These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35416591)

  • 1. Chaos to Clarity: Pragmatic Approaches to Overcome Challenges for Successful Implementation of Additional Risk Minimisation Measures in the European Union and the UK by a Marketing Authorisation Holder.
    Hapani K; Parikh N; Pianka K; Patel H
    Pharmaceut Med; 2022 Jun; 36(3):173-188. PubMed ID: 35416591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
    Rubino A; Artime E
    Expert Opin Drug Saf; 2017 Aug; 16(8):877-884. PubMed ID: 28548608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
    Agyemang E; Bailey L; Talbot J
    Pharmaceut Med; 2017; 31(2):101-112. PubMed ID: 28413313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
    Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union.
    Ramirez I
    Ger Med Sci; 2015; 13():Doc21. PubMed ID: 26633964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional risk minimisation measures in the EU - are they eligible for assessment?
    Zomerdijk IM; Trifirò G; Sayed-Tabatabaei FA; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1046-53. PubMed ID: 23946274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
    Ruof J; Staab T; Dintsios CM; Schröter J; Schwartz FW
    Health Econ Rev; 2016 Dec; 6(1):46. PubMed ID: 27687714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-marketing authorisation submission assessments in Europe.
    Morgan L
    Therapie; 2005; 60(3):205-8. PubMed ID: 16128260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical Considerations for the Implementation and Monitoring of Risk Minimisation Measures for High-Risk Teratogenic Medicines.
    Mueller M; Peakin J; Lewis DJ
    Pharmaceut Med; 2023 Nov; 37(6):439-449. PubMed ID: 37594662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union.
    de Jong AJ; Santa-Ana-Tellez Y; van Thiel GJMW; Zuidgeest MGP; Siiskonen SJ; Mistry D; de Boer A; Gardarsdottir H;
    Clin Pharmacol Ther; 2021 Jun; 109(6):1517-1527. PubMed ID: 33666223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European regulations relevant to the marketing and use of fish vaccines.
    Lee A
    Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.